Instantly screen for COVID-19 using only a smartphone

ResApp is developing the world’s first COVID-19 instant screening test that will use cough sounds to indicate the presence of a COVID-19 infection.

ResApp has previously developed the only regulatory approved diagnostic for respiratory disease using cough sounds analysed on a smartphone. This experience uniquely positions the company to deliver an instant screening test for COVID-19 and its variants that will have applications for consumers, businesses and governments globally.

By using its large dataset of clinically-labelled non-COVID-19 cough samples, including coughs from patients with non-COVID-19 lower respiratory tract infections, ResApp will be able to ensure that any COVID-19 screening test developed accurately identifies COVID-19 and not other respiratory diseases.

ResApp has two clinical trials currently recruiting patients in the United States to collect cough sounds, symptoms and validated COVID-19 status through PCR testing. It has also announced an additional trial in India. These studies will generate the high quality data, backed by accurate ground truth labelling through PCR testing, that is needed to train a robust machine learning algorithm. The studies are also collecting PCR test cycle thresholds, allowing evaluation of algorithm sensitivity to viral load.

Clinical studies

NCT04864535
A Pilot Study for the Collection Of Vocalized, Individual Digital Cough Sound Recordings to Screen for COVID-19 (COVID-Cough)

NCT04989452
Cough Sound Recordings to Understand COVID-19-like Symptom Progression to Understand COVID-19-like Symptom Progression

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St,
Brisbane, QLD 4000, Australia

  

© 2021 ResApp Health Limited. All rights reserved.